Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US6285301072
Ticker MYL
Company MYLAN
Currency $
Price
Aware Investor Index (AII) 0.0039
Recommendation STRONG SELL
P/E 40.39
ROE 3.57 %
Capitalization 19,192,392,000 $
Dividend Yield 0.00 %
P/S 1.61
AII Position 653
P/E Position 548
ROE Position 674
Capitalization Position 359
Dividend Yield Position 595
Sales 11,907,700,000 $
10-Year Average Earnings 475,123,700 $
Shares Outstanding 536,700,000
Equity 13,307,600,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country United States
MYLAN Investor Relations Web Site http://www.mylan.com/investors/public-filings







Sales:

YEAR MONTH AMOUNT
2017 12 11,907,700,000.00 $
2016 12 11,076,900,000.00 $
2015 12 9,429,300,000.00 $
2014 12 7,719,600,000.00 $
2013 12 6,909,143,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 696,000,000.00 $
2016 12 480,000,000.00 $
2015 12 847,600,000.00 $
2014 12 929,400,000.00 $
2013 12 623,711,000.00 $
2012 12 640,850,000.00 $
2011 12 536,810,000.00 $
2010 12 223,580,000.00 $
2009 12 93,536,000.00 $
2008 12 -320,250,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 13,307,600,000.00 $
2016 12 11,117,600,000.00 $
2015 12 9,765,800,000.00 $
2014 12 3,276,000,000.00 $
2013 12 2,959,907,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 536,700,000
2016 12 520,500,000
2015 12 497,400,000
2014 12 398,000,000
2013 12 394,454,000

 












Bloomberg News for MYLAN:



Google News for MYLAN:

Seeking Alpha - 2 days ago
Mylan: On The Road To Recovery
US pharmaceutical company Mylan (MYL) has struggled this year due to a series of poor earnings releases and operational setbacks. However ...
Marea Informative (blog)
Mylan May Make Generics but Its Charts are Starting to Look 'Name ...
A recommendation from Jim Cramer of MYL is a good place to start but let's do a quick check of the charts and indicators to see if this is a good ...
The RNS Daily
Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3
The FDA completed an inspection at Mylan's plant in Morgantown, West Virginia earlier this year and made observations through a Form 483.
Baseball Daily News
Mylan (MYL) Upgraded by ValuEngine to Sell
ValuEngine upgraded shares of Mylan (NASDAQ:MYL) from a strong sell rating to a sell rating in a report issued on Tuesday. Other equities ...
TheStreet.com - 37 minutes ago
Wall Street thought Mylan was headed for disaster—now, analysts ...
But like Chicken Little in the famous folk tale, they seem to have been wrong. Mylan's MYL, -2.77% third-quarter results, which included a profit ...
Zacks.com - 6 Nov 2018
Mylan (MYL) Surpasses Q3 Earnings Estimates
Mylan (MYL) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.17 per share. This compares to ...
Seeking Alpha
Theravance Biopharma (TBPH), Mylan (MYL) Receive FDA ...
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that the ...
Motley Fool
There is a convincing reason to buy: Edison International (EIX ...
According to the Composite Indicator, Trendspotter rated the MYL stock as “Buy”. In the short-term, Mylan N.V. (MYL) has a 20-day average ...
StreetInsider.com
Analysts Ranking Activities: Mylan NV (MYL)
Mylan N.V. (MYL) stock price ended its day with loss -0.50% and finalized at the price of $35.76, its 52 week- peak value and changed 17.90% ...
Fairfield Current - 7 Nov 2018
Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?
Concurrent with second-quarter results, Mylan lowered its annual outlook as a result of the change in expected product launches and resizing ...


Back